D
David W. Johnstone
Researcher at Medical College of Wisconsin
Publications - 47
Citations - 5534
David W. Johnstone is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Lung cancer & Radiation therapy. The author has an hindex of 20, co-authored 47 publications receiving 5015 citations. Previous affiliations of David W. Johnstone include Virginia Military Institute & University of Rochester.
Papers
More filters
Journal ArticleDOI
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman,Rebecca Paulus,James M. Galvin,Jeff M. Michalski,William L. Straube,Jeffrey D. Bradley,Achilles J. Fakiris,Andrea Bezjak,Gregory M.M. Videtic,David W. Johnstone,Jack F. Fowler,Elizabeth Gore,Hak Choy +12 more
TL;DR: Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
Journal ArticleDOI
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Gary M. Strauss,James E. Herndon,Michael A. Maddaus,David W. Johnstone,Elizabeth Johnson,David H. Harpole,Heidi H. Gillenwater,Dorothy Watson,David J. Sugarbaker,Richard L. Schilsky,Everett E. Vokes,Mark R. Green +11 more
TL;DR: A statistically significant survival advantage for patients who had tumors > or = 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors, and CALGB 9633 was underpowered to detect small but clinically meaningful improvements.
Journal ArticleDOI
Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians.
TL;DR: These guidelines could be used as a guide to hospital nursing, respiratory therapy and administrative departments who wish to develop these services and dedicated operators who display competency in these individual procedures should have less difficulty overcoming the barriers that sometimes exist within local hospital credentialing committees.
Journal ArticleDOI
Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
Gary M. Strauss,James E. Herndon,Michael A. Maddaus,David W. Johnstone,Elizabeth Johnson,D. M. Watson,David J. Sugarbaker,Richard L. Schilsky,Mark R. Green +8 more
TL;DR: Adjuvant chemotherapy significantly reduces all-cause and lung cancer mortality in stage IB NSCLC and is the first randomized trial to demonstrate significantly improved survival for a carboplatin-based adjuvant chemotherapy regimen in a uniform population withNSCLC.
Journal ArticleDOI
Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer
R.D. Timmerman,Chen Hu,J.M. Michalski,William L. Straube,James M. Galvin,David W. Johnstone,Jeffrey D. Bradley,R.B. Barriger,Andrea Bezjak,Gregory M.M. Videtic,Lucien A. Nedzi,Maria Werner-Wasik,Yuhchyau Chen,R.U. Komaki,Hak Choy +14 more
TL;DR: This validated model demonstrates that operability, tumor diameter, PTV size, BED10 and age form the basis of a new risk stratification for OS in stage I NSCLC patients treated with SABR that may help define subgroups for future clinical trials.